Simcere Pharmaceutical Group Limited

2096

HK0000658531

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
5.3 ^HKD	+1.15%		+2.91%	-21.25%

Apr. 25	Simcere Pharmaceutical’ Profit Down 23% in 2023	MT
Apr. 10	Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	MT

Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024

March 20, 2024 at 10:32 am EDT

Simcere Pharmaceutical Group Limited proposed final dividend of RMB 0.16 per share for the year ended December 31, 2023. Ex-dividend date 18 June 2024, Record date 25 June 2024 and Payment date 15 July 2024. Date of shareholders' approval 14 June 2024.

Latest news about Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical’ Profit Down 23% in 2023	Apr. 25	MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	Apr. 09	MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	Apr. 09	CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	Mar. 20	MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	Mar. 20	CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	Mar. 17	MT
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	Mar. 15	CI
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	Mar. 13	MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	Mar. 12	CI
Simcere Pharmaceutical Group's New Anti-Cancer Drug Gets Clinical Trials Approval from the FDA	Mar. 10	MT
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500	Mar. 10	CI
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama	Feb. 20	CI
Simcere Pharma's Ischemic Stroke Treatment Results Published in US Neurology Journal	Feb. 20	MT
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	Feb. 19	MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	Feb. 19	MT
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Feb. 18	CI
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19	Jan. 18	CI
Simcere Pharma Unit's Shareholders Approve Order Collection Agreement	Jan. 17	MT
China Grants Clinical Trial Approval for Simcere Pharmaceutical's Anti-Tumor Medication	Jan. 15	MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets	Jan. 12	CI
Simcere Pharmaceutical Group Limited Announces the Phase III Clinical Study of Suvemcitug for Injection in the Treatment of Platinum-Resistant Ovarian Cancer Has Successfully Met the Primary Study Endpoint	Jan. 03	CI
Simcere Pharmaceutical’s Phase Three Cancer Trial Meets Primary Endpoint	Jan. 03	MT
Simcere Pharmaceutical Unit to Buy Production Facility in Jiangsu Province for 42 Million Yuan	Jan. 01	MT
Simcere Pharma Gets Authorization to Produce Imported Cancer Drug in Hainan Facility	Dec. 28	MT

Chart Simcere Pharmaceutical Group Limited

Duration

Period

Chart Simcere Pharmaceutical Group Limited

More charts

Company Profile

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Simcere Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.906 CNY

Average target price

7.984 CNY

Spread / Average Target

+62.73%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SIMCERE PHARMACEUTICAL GROUP LIMITED	-21.25%	1.74B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals